image

Immuno-Oncology

Innovative Drugs Designed to Improve Patients’ Lives

Our pipeline includes internally discovered and wholly owned drug-candidates designed to treat patients with hematologic malignancies, solid tumors, autoimmune diseases, and viral diseases. It comprises both Chimeric Targeting Molecules (CTMs) for targeted protein degradation to eliminate disease causing proteins and Ligase Inhibitors that target key control elements in immune regulation. Drug discovery alliances with Gilead Sciences and Sanofi further enhance our pipeline, each focusing on the discovery and development of CTMs against a set of unique targets.

Building Immunity to Cancer: Nurix’s Immuno-Oncology Program

CBL-B Inhibition

Casitas B-lineage lymphoma proto-oncogene-b (CBL-B) is an E3 ligase that is expressed in immune cells and in the context of cancer, acts as a brake on the immune system. CBL-B functions as an intracellular checkpoint that negatively regulates T cell activation, NK cell activity, and immune response through degradation of specific proteins.

Conversely, inhibition of CBL-B with a small molecule drug activates T cells, a goal in the treatment of cancer, where T cells and the entire immune system can be mobilized to destroy a tumor. Nurix has developed two CBL-B inhibitors, NX-1607 for oral administration and NX-0255 for Adoptive Cell Therapy.

Drug CandidateTarget (Delivery)Therapeutic AreaDiscoveryLead OptimizationPreclinicalPhase 1Phase 2Phase 3
Protein Degradation Chimeric Targeting Molecule (CTM) Portfolio
NX-2127 BTK + IMiD Activity (Oral) B-cell malignancies

 

NX-5948 BTK (Oral) B-cell malignancies and autoimmune disease

 

KINASE-CTM3 Undisclosed T-cell malignancies and autoimmune disease

 

COVID-CTMs 3 targets Anti-viral

 

Drug CandidateTarget (Delivery)Therapeutic AreaDiscoveryLead OptimizationPreclinicalPhase 1Phase 2Phase 3
Ligase Inhibitor Portfolio
NX-1607 CBL-B (Oral) Immuno-oncology

 

DeTIL-0255 CBL-B (ex vivo) Tumor infiltrating lymphocytes

 

LIGASE-INH2 Undisclosed Immuno-oncology

 

Drug CandidateTarget (Delivery)Therapeutic AreaDiscoveryLead OptimizationPreclinicalPhase 1Phase 2Phase 3
Partners and Subsidiaries
DeCART CBL-B and others (ex vivo) Chimeric antigen receptor T‑cells (CAR-T)

 

Gilead Sciences 5 targets Undisclosed

Undisclosed Progress

 

Sanofi 5 targets Undisclosed

Undisclosed Progress

 

Candidate / TargetPhase
Protein Degradation Chimeric Targeting Molecule (CTM) Portfolio
NX-2127
BTK + IMiD Activity (Oral)
Phase 1
NX-5948
BTK (Oral)
Preclinical
KINASE-CTM3
Undisclosed
Lead Optimization
COVID-CTMs
3 targets
Discovery
Ligase Inhibitor Portfolio
NX-1607
CBL-B (Oral)
Phase 1
DeTIL-0255
CBL-B (ex vivo)
Preclinical
LIGASE-INH2
Undisclosed
Lead Optimization
Partners and Subsidiaries
DeCART
CBL-B and others (ex vivo)
Lead Optimization
Gilead Sciences
5 targets
Undisclosed Progress
Sanofi
5 targets
Undisclosed Progress

NX-1607 (oral CBL-B inhibitor for solid tumors)

NX-1607 is an oral, small molecule CBL-B inhibitor. In preclinical animal models of both colorectal cancer and triple negative breast cancer, NX-1607 demonstrates anti-tumor activity and prolongs survival. The combination of NX-1607 with an anti-PD-1 antibody provides additional benefit in animal models. The anti-tumor activity of NX-1607 is dependent on both CD8+ T cells and NK cells.

We are planning to develop NX-1607 in multiple solid tumors as monotherapy or in combination with other complementary therapies such as anti-PD-1 antibodies. A Phase 1 clinical trial of NX-1607 as a single agent therapy in multiple oncology indications is ongoing.